SR One leads $55M round for nasal al­ter­na­tive to EpiPen; Sanofi pulls web­site over ac­cu­ra­cy con­cerns

Cal­i­for­nia-based bio­phar­ma com­pa­ny ARS Phar­ma­ceu­ti­cals said to­day that they have closed on a Se­ries D round of $55 mil­lion. The round was led by SR One, with RA Cap­i­tal Man­age­ment and Deer­field Man­age­ment par­tic­i­pat­ing.

ARS is us­ing the mon­ey to ad­vance its drug Neffy, an ep­i­neph­rine nasal spray, through FDA ap­proval and ini­tial launch to con­sumers as an easy-to-use al­ter­na­tive to EpiPen for se­vere al­ler­gic re­ac­tions.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER